Three conditions bring people to this class off-label. They sit at very different evidence levels — PCOS has randomised human trials behind it, the other two have mechanism and inference. Each carries an interaction the general framing misses.
No approval, no trial
Semaglutide is approved for obesity and type 2 diabetes. Use in PCOS, hypothyroidism or fibromyalgia is off-label unless an approved indication is independently met — though unlike almost everything else in this library, the PCOS case rests on human trial evidence rather than inference.
The fertility and contraception item below is the single most important thing on this page for anyone with PCOS.
Observational — and the investigators said what it does not show
Smoking cessation — a large signal, and the authors’ own warning
Pathophysiology
Nicotine dependence runs through mesolimbic dopamine reward signalling. GLP-1 receptors are expressed in those circuits, and in animal models GLP-1 agonism reduces nicotine self-administration and blunts withdrawal-related overeating.
Mechanistic rationale
A target trial emulation using electronic health records in people with type 2 diabetes reported that semaglutide was associated with a lower risk of medical encounters for tobacco dependence against all seven comparator antidiabetic drugs — the largest effect against insulins and the smallest, still significant, against other GLP-1 agonists — along with fewer cessation-medication prescriptions and less counselling. Published in a major internal medicine journal in July 2024.
Community reports
The investigators wrote the caveat themselves, and it is worth quoting the shape of it: the limitations of retrospective health-record work — confounding, misdiagnosis, ascertainment — preclude firm conclusions, and the results should not be read as justifying off-label use for smoking cessation. That is a research team declining to overstate its own finding, which is rarer than it should be and is exactly the standard this site tries to hold.
Components carrying the argument: GLP-1 receptor in mesolimbic circuits
Approved — randomised outcome trials
Type 2 diabetes — the approved indication
Pathophysiology
Type 2 diabetes is insulin resistance plus progressive beta-cell failure. Lowering glucose is the easy part; lowering cardiovascular and renal events is what changes the outlook.
Mechanistic rationale
The SUSTAIN programme established glycaemic efficacy — HbA1c reductions in the region of 1.5 to 1.8 percentage points, larger than the earlier agents in the class. SUSTAIN-6 reported a reduction in major adverse cardiovascular events, driven predominantly by non-fatal stroke, and FLOW subsequently reported a renal benefit in type 2 diabetes with chronic kidney disease. Oral semaglutide (Rybelsus) covers the same indication with a different absorption problem to solve.
Community reports
The most common grey-market pattern is people with diagnosed type 2 diabetes sourcing research-grade material because the prescription product is unaffordable or unavailable. That substitution swaps a known-content pen for an unknown-content vial in a condition where a dosing error interacts with insulin or a sulphonylurea to produce hypoglycaemia.
Components carrying the argument: GLP-1 receptor — glucose-dependent insulin release, glucagon suppression, gastric emptying delay
Randomised human evidence (class)
PCOS — metabolic and reproductive
Pathophysiology
Insulin resistance drives hyperinsulinaemia, which stimulates ovarian theca cells to overproduce androgens and suppresses SHBG — raising free testosterone, disrupting follicular development and producing anovulation. Weight gain worsens insulin resistance, closing the loop.
Mechanistic rationale
This class breaks the loop at its origin. Reducing hyperinsulinaemia lowers ovarian androgen output and raises SHBG; weight loss independently improves insulin sensitivity. Randomised trials of GLP-1 receptor agonists in PCOS report improved insulin sensitivity, reduced androgens, weight loss and improved menstrual regularity — strongest for liraglutide and exenatide, with semaglutide data emerging.
Community reports
Widely reported weight loss, return of regular cycles, reduced hirsutism and acne over months. The cycle reports describe the syndrome’s defining feature rather than a peripheral symptom.
Components carrying the argument: Incretin pathway — independent of the ovary itself
Labelled — act on this
Fertility returns — often unexpectedly
Pathophysiology
Anovulation is a defining feature of PCOS, and many people with it have assumed for years that conception is difficult. Restoring insulin sensitivity and losing 5%—10% of body weight restores ovulation in a substantial proportion.
Mechanistic rationale
Ovulation returning means fertility returning. This class is contraindicated in pregnancy and labels require discontinuation beforehand — two months for semaglutide, one month for tirzepatide. Tirzepatide is additionally labelled as reducing oral contraceptive effectiveness, with backup or non-oral contraception advised for four weeks after starting and after each dose increase, because delayed gastric emptying alters absorption.
Community reports
Unplanned pregnancies on this class in PCOS populations are reported often enough to have acquired an informal nickname. The mechanism is entirely predictable and the risk entirely manageable — if anyone mentions it.
Components carrying the argument: Class-wide; the oral contraceptive interaction is tirzepatide-specific
Off-label — mechanism independent of thyroid
Hypothyroidism
Pathophysiology
Low thyroid hormone lowers basal metabolic rate and promotes fluid retention. The weight gain directly attributable to hypothyroidism is modest — a few kilograms, much of it water — and largely resolves with adequate replacement.
Mechanistic rationale
The drug acts independently of thyroid status. But sequencing matters: if TSH is not in range, correcting replacement is the first intervention and it is free. The specific hazard is that delayed gastric emptying alters levothyroxine absorption — a narrow-therapeutic-index drug that is fasting-dependent and absorption-sensitive. Direction of change is not reliably predictable.
Community reports
Feeling "off" on this class — fatigue and cold, or palpitations and anxiety — is almost always blamed on the drug. In a replaced person those are also the symptoms of drifting out of range, and only a blood test tells them apart.
Components carrying the argument: Interaction is via gastric emptying
Theorized — weight link better supported than the inflammation one
Fibromyalgia
Pathophysiology
A disorder of central pain processing, with non-restorative sleep, fatigue and cognitive symptoms. Obesity is genuinely associated with worse fibromyalgia symptoms, and weight loss has been reported to improve them.
Mechanistic rationale
The mechanical-load and weight argument is reasonable and has observational support. The inflammation argument is weaker than it sounds: fibromyalgia is not an inflammatory disease — CRP is typically normal or only minimally raised — so "lowering the inflammatory baseline" is addressing something that is not clearly elevated to begin with.
Community reports
Reported reductions in pain and improved mobility alongside weight loss. Difficult to separate from the effect of weight loss by any means, which is the point rather than a criticism.
Components carrying the argument: Weight and mechanical load, not central pain processing
What actually has evidence for these conditions
PCOS has treatments that work. Metformin is first-line for the metabolic phenotype; combined hormonal contraceptives address hyperandrogenism and cycle regulation; letrozole is first-line for ovulation induction; inositol has reasonable evidence and an excellent safety profile; approved GLP-1 receptor agonists now have randomised evidence in this population. Weight loss of 5–10% alone restores ovulation in a meaningful proportion.
Levothyroxine is inexpensive, once daily, titrated against a reliable blood test, and restores euthyroid status in most people. Nothing here treats the thyroid. The unglamorous first move in someone still gaining weight is confirming replacement is adequate and correctly taken — fasting, away from calcium, iron, coffee and proton pump inhibitors.
Fibromyalgia has approved pharmacotherapy — pregabalin, duloxetine and milnacipran — and the intervention with the strongest evidence of any kind is graded exercise combined with cognitive behavioural therapy. Sleep is also worth taking seriously: non-restorative sleep is close to universal in fibromyalgia and obstructive sleep apnoea is under-diagnosed in this population.
Note what duloxetine and milnacipran are: serotonin–noradrenaline reuptake inhibitors. The treatments that work in fibromyalgia act centrally, on pain processing. That is the yardstick any peptide rationale should be measured against.
On the boxed warning: the contraindication covers medullary thyroid carcinoma and MEN2, from rodent C-cell findings. That is a specific, uncommon cancer of the parafollicular cells — not Hashimoto thyroiditis, autoimmune thyroid disease, thyroid nodules or goitre, all of which are common and cause avoidable alarm here.
A practical note for fibromyalgia: irritable bowel syndrome is highly comorbid with fibromyalgia, and this class produces substantial gastrointestinal adverse effects. That combination is worth anticipating rather than discovering.
